May 11, 2022

Unlearn Raises Series B Funding to Advance Use of TwinRCT in Clinical Trials

Machine learning technology developer Unlearn has raised $50 million in a Series B funding round led by US venture capital and private equity firm Insight Partners to advance the use of TwinRCTs in clinical trials.

New investor Radical Ventures and the company’s current investors including DCVC, 8VC, Mubadala Capital Ventures and DCVC Bio participated in the funding round.

Unlearn intends to use the proceeds to advance the use of its machine learning-based twinRCTs in trials.

The company works with biotech companies, pharmaceutical sponsors and academic institutes to streamline human clinical trials with TwinRCT.

Randomized trial, TwinRCT relies on machine learning and historical data to increase the chances of success with fewer patients.

In TwinRCTs, participants are assigned to treatment and control arms similar to a standard randomized controlled trial (RCT), but a digital twin is calculated for each patient using a machine learning model trained on control data historical compared to traditional ECR.

After modifying each patient’s prognostic score obtained from their digital twin, treatment impacts for primary and secondary outcomes can be calculated with increased accuracy.

As part of the funding, Insight Partners managing director Dylan Morris has joined Unlearn’s board of directors.

Unlearn Founder and CEO Charles Fisher said, “Unlearn continues to make rapid progress as we expand our work with global biopharmaceutical companies and advance productive conversations with global regulators who are committed to supporting innovation. in clinical trials.

“This new funding is validation of our growing footprint in clinical trials.”

In February this year, the company signed a multi-year partnership with Merck KGaA, Darmstadt, Germany, which leverages TwinRCTs to integrate predictive information from digital twins into its randomized controlled trials.

Related companies


Source link